on-intervention study to the capture of the quality of life with the adult patients who receive Akynzeo to the prevention from nausea and vomiting caused by highly or moderate emetogenic chemotherapy
- Conditions
- chemotherapy induced nausea and vomitingC00-C97R11Malignant neoplasmsNausea and vomiting
- Registration Number
- DRKS00009316
- Lead Sponsor
- RIEMSER Pharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 2173
Inclusion Criteria
• Signed patient consent form
• Age: = 18 Years
• 1- or 2-day chemotherapy, high or moderate emetogen
• anti-emetic prevention with Akynzeo® according to the summary of product characteristics
Exclusion Criteria
• Patients without chemotherapy
• radiotherapy alone
• brain tumour, symptomatic brain metastases
• anticipatory nausea and vomiting
• not chemotherapy-induced nausea and vomiting on the basis of other disorders or drugs
• chemotherapies that last more than 2 days within a chemotherapy cycle
• pregnancy
• hypersensitivity to the active substances, excipient or other constituent materials of Akynzeo®
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method